These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10265096)

  • 21. A survey exploring knowledge and perceptions of general practitioners towards the use of generic medicines in the northern state of Malaysia.
    Chua GN; Hassali MA; Shafie AA; Awaisu A
    Health Policy; 2010 May; 95(2-3):229-35. PubMed ID: 20044165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of legislative changes in drug promotion on medical students: questionnaire survey.
    Vuorenkoski L; Valta M; Helve O
    Med Educ; 2008 Dec; 42(12):1172-7. PubMed ID: 19120947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What is missing on their web sites? An evaluation of national and international pharmaceutical companies in Turkey.
    Yegenoglu S; Aslan D; Acar A; Calgan Z
    Telemed J E Health; 2005 Dec; 11(6):684-91. PubMed ID: 16430388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of generic drug competition on the price of prescription drugs in Ontario.
    Lexchin J
    CMAJ; 1993 Jan; 148(1):35-8. PubMed ID: 8439888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opinions of pharmacy, medicine, and pharmaceutical industry leaders about hypothetical therapeutic-interchange legislation.
    Segal R; Grines LL; Pathak DS
    Am J Hosp Pharm; 1988 Mar; 45(3):570-7. PubMed ID: 3369459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brands or generics: the dilemma of pharmaceutical marketing in a developing country.
    Quraeshi ZA; Luqmani M; Malhotra N
    J Health Care Mark; 1983; 3(4):27-37. PubMed ID: 10264767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Costs to physician offices of providing medications to medically indigent patients via pharmaceutical manufacturer prescription assistance programs.
    Clay P; Vaught E; Glaros A; Mangum S; Hansen D; Lindsey C
    J Manag Care Pharm; 2007; 13(6):506-14. PubMed ID: 17672812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Global marketing of cholesterol-lowering drugs as therapy.
    Elimimian JU; Gilmore JM; Singletary TJ
    J Hosp Mark Public Relations; 2006; 16(1-2):15-28. PubMed ID: 17194684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
    Fleuranceau-Morel P
    Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Evaluation of information for generic drugs based on importance and necessity].
    Iijima H; Kamei M; Koshimizu T; Shiragami M
    Yakugaku Zasshi; 2005 Sep; 125(9):739-47. PubMed ID: 16141694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse-drug-event data provided by pharmaceutical companies.
    Cudny ME; Graham AS
    Am J Health Syst Pharm; 2008 Jun; 65(11):1071-5. PubMed ID: 18499882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generics: keep a balanced view.
    Prescrire Int; 2014 Feb; 23(146):52-5. PubMed ID: 24669392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What's in a name? Generics and the persistence of the pharmaceutical brand in American medicine.
    Greene JA
    J Hist Med Allied Sci; 2011 Oct; 66(4):468-506. PubMed ID: 20858701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strategies That Delay Market Entry of Generic Drugs.
    Vokinger KN; Kesselheim AS; Avorn J; Sarpatwari A
    JAMA Intern Med; 2017 Nov; 177(11):1665-1669. PubMed ID: 28975217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Information responsibilities of generic drug companies.
    Cramer R
    Am J Hosp Pharm; 1986 Jul; 43(7):1674, 1679. PubMed ID: 3752098
    [No Abstract]   [Full Text] [Related]  

  • 38. Consistency in the safety labeling of bioequivalent medications.
    Duke J; Friedlin J; Li X
    Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):294-301. PubMed ID: 23042584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Confusing brand names: nightmare of medical profession.
    Rataboli PV; Garg A
    J Postgrad Med; 2005; 51(1):13-6. PubMed ID: 15793332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan.
    Rohra DK; Gilani AH; Memon IK; Perven G; Khan MT; Zafar H; Kumar R
    J Pharm Pharm Sci; 2006; 9(1):50-9. PubMed ID: 16849008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.